Andrew X. Zhu

机构：Johns Hopkins University, Drexel University, Icahn School of Medicine at Mount Sinai · ORCID：0000-0003-4873-5033

发表论文 809 篇 · 总被引 81172 次 · h-index 116

代表论文

• Precision treatment in advanced hepatocellular carcinoma (2024 · Cancer Cell · 被引 415)
• Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023 · JAMA Oncology · 被引 258)
• Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 87)
• A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma (2024 · Annals of Oncology · 被引 38)
• Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study (2024 · Liver Cancer · 被引 9)
• Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation (2025 · Nature Communications · 被引 8)